Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximab
- 22 December 2005
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 76 (2), 119-123
- https://doi.org/10.1111/j.1600-0609.2005.00570.x
Abstract
Multicentric Castleman's disease (MCD) is an indolent lymphoproliferative disorder. The pathogenesis of MCD has not been established, and its treatment remains uncertain. Several authors have described the relationship of human herpes virus type 8 (HHV-8) to MCD in human immunodeficiency virus (HIV)-positive patients. Recently, anti-CD20 monoclonal antibody (rituximab) is increasingly being used to treat HIV-positive MCD; although it is uncertain whether rituximab is effective for HIV-negative patients with MCD. To explore the benefit of rituximab for HIV-negative patients with MCD, we describe the clinical and biologic course in three HIV-negative patients with MCD, and examined the relationship of HHV-8 infection to HIV-negative MCD. Their polymerase chain reaction analyses for the HHV-8 sequence in peripheral blood were negative, and there was no relationship between HHV-8 infection and symptoms of HIV-negative MCD. Two of three patients (66%) achieved a near complete remission with no clinical symptoms due to MCD with a follow-up of 16-40 months after rituximab administration. One of the three patients presented no clinical remission of MCD after rituximab administration, although a significant decrease of inflammatory parameters was observed. These findings suggest that rituximab treatment may be an appropriate first-line therapy for HIV-negative MCD.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomenaAmerican Journal of Hematology, 2005
- Complete Remission with Anti-CD20 Therapy for Unicentric, Non-HIV-Associated, Hyaline-Vascular Type, Castleman's DiseaseCancer Investigation, 2005
- Evan's syndrome complicating multicentric Castleman's disease - dramatic response to rituximabEuropean Journal of Haematology, 2004
- Resolution of AIDS-related Castleman's Disease with Anti-CD20 Monoclonal Antibodies is Associated with Declining IL-6 and TNF-α LevelsLeukemia & Lymphoma, 2004
- Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatmentBlood, 2004
- Multicentric Castleman's diseaseAIDS, 2004
- Rituximab therapy for HIV-associated Castleman diseaseBlood, 2003
- A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibodyAnnals of Hematology, 2003
- Prolonged remission of HIV-associated multicentric Castelmanʼs disease with an anti-CD20 monoclonal antibody as primary therapyAIDS, 2003
- An Unusual Cluster of Cases of Castleman's Disease during Highly Active Antiretroviral Therapy for AIDSNew England Journal of Medicine, 1999